Literature DB >> 13507398

Studies on the carcinostatic activity in mice of 6-azauracil riboside (azauridine), in comparison with that of 6-azauracil.

J J JAFFE, R E HANDSCHUMACHER, A D WELCH.   

Abstract

Entities:  

Keywords:  CYTOTOXIC DRUGS; NUCLEOSIDES AND NUCLEOTIDES/effects; URACIL/antagonists

Mesh：

Substances：

Year:  1957        PMID： 13507398      PMCID： PMC2603694     

Source DB:  PubMed          Journal:  Yale J Biol Med        ISSN： 0044-0086


× No keyword cloud information.
  10 in total

1.  Studies of bacterial resistance to 6-azauracil and its riboside.

Authors:  R E HANDSCHUMACHER
Journal:  Biochim Biophys Acta       Date:  1957-02

2.  Ribosidation as a means of activating 6-azauracil as an inhibitor of cell reproduction.

Authors:  R SCHINDLER; A D WELCH
Journal:  Science       Date:  1957-03-22       Impact factor: 47.728

3.  The anticancerous action of 6-azauracil (3, 5-dioxo-2, 3, 4, 5-tetrahydro-1, 2, 4-triazine).

Authors:  F SORM; A JAKUBOVIC; L SLECHTA
Journal:  Experientia       Date:  1956-07-15

4.  Microbial studies of 6-azauracil, an antagonist of uracil.

Authors:  R E HANDSCHUMACHER; A D WELCH
Journal:  Cancer Res       Date:  1956-11       Impact factor: 12.701

5.  Studies on the mechanism of action 6-azathymine. II. Azathymine deoxyriboside, a microbial inhibitor.

Authors:  W H PRUSOFF; A D WELCH
Journal:  J Biol Chem       Date:  1956-02       Impact factor: 5.157

6.  Biological investigations of 6-azathymine, a thymine analog.

Authors:  W H PRUSOFF; W L HOLMES; A D WELCH
Journal:  Cancer Res       Date:  1954-09       Impact factor: 12.701

7.  Electroencephalographic and neurological changes induced in man by the administration of 1, 2,4-triazine-3,5 (2H, 4H)-dione (6-azauracil).

Authors:  C E WELLS; C AJMONE-MARSAN; E FREI; J H TUOHY; B I SHNIDER
Journal:  Electroencephalogr Clin Neurophysiol       Date:  1957-05

8.  Biological studies of analogs of orotic acid: 6-uracilsulfonic acid, 6-uracilsulfonamide, and 6-uracil methyl sulfone.

Authors:  W L HOLMES; A D WELCH
Journal:  Cancer Res       Date:  1956-03       Impact factor: 12.701

9.  Effect of the deoxyriboside of 6-azathymine (azathymidine) on the biosynthesis of deoxyribonucleic acid by bone marrow and neoplastic cells (in vitro).

Authors:  W H PRUSOFF; L G LAJTHA; A D WELCH
Journal:  Biochim Biophys Acta       Date:  1956-04

10.  Studies on the mode of action of analogues of orotic acid; 6-uracilsulfonic acid, 6-uracilsulfonamide, and 6-uracil methyl sulfone.

Authors:  W L HOLMES
Journal:  J Biol Chem       Date:  1956-12       Impact factor: 5.157
  10 in total
  7 in total

1.  The uricosuria and orotic aciduria induced by 6-azauridine.

Authors:  H J FALLON; E FREI; J BLOCK; J E SEEGMILLER
Journal:  J Clin Invest       Date:  1961-10       Impact factor: 14.808

2.  Six-Azauracil Treatment of Experimental Avian Lymphomatosis.

Authors:  V L Sanger
Journal:  Can J Comp Med Vet Sci       Date:  1962-01

Review 3.  New indications for 6-azauridine treatment in man. A review.

Authors:  J Elis; H Rasková
Journal:  Eur J Clin Pharmacol       Date:  1972-03       Impact factor: 2.953

Review 4.  The Role of Fluoropirimidines in Gastrointestinal Tumours: from the Bench to the Bed.

Authors:  Jorge Hernando-Cubero; Ignacio Matos-García; Vicente Alonso-Orduña; Jaume Capdevila
Journal:  J Gastrointest Cancer       Date:  2017-06

5.  Chemical interference with DSIF complex formation lowers synthesis of mutant huntingtin gene products and curtails mutant phenotypes.

Authors:  Ning Deng; Yun-Yun Wu; Yanan Feng; Wen-Chieh Hsieh; Jen-Shin Song; Yu-Shiuan Lin; Ya-Hsien Tseng; Wan-Jhu Liao; Yi-Fan Chu; Yu-Cheng Liu; En-Cheng Chang; Chia-Rung Liu; Sheh-Yi Sheu; Ming-Tsan Su; Hung-Chih Kuo; Stanley N Cohen; Tzu-Hao Cheng
Journal:  Proc Natl Acad Sci U S A       Date:  2022-08-01       Impact factor: 12.779

6.  Problems in the Designing of Antimetabolites.

Authors:  H G Mautner
Journal:  Yale J Biol Med       Date:  1960-04

Review 7.  Standing the test of time: targeting thymidylate biosynthesis in cancer therapy.

Authors:  Peter M Wilson; Peter V Danenberg; Patrick G Johnston; Heinz-Josef Lenz; Robert D Ladner
Journal:  Nat Rev Clin Oncol       Date:  2014-04-15       Impact factor: 66.675
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.